Colic

BASEL, Switzerland I October 23, 2024 I AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal diseases announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP in Frontiers in Immunology – Nutritional Immunology ( https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full ). AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine. AMYNOPEP is designed to break down hard-to-digest gluten peptides into harmless and absorbable single amino acids and dipeptides, thereby supporting individuals with gluten-related health disorders in avoiding exposure to inflammatory peptides. AMYRA’s first-in-human clinical study assessed gluten-digesting enzyme efficacy using high-resolution analytics and demonstrated in near-real-time that AMYNOPEP swiftly and significantly enhanced the digestion of proteolytically-resistant, immunogenic gluten peptides in healthy volunteers. A team of researchers from AMYRA and the University of Greifswald (Germany) evaluated AMYNOPEP’s digestive efficacy on the degradation of a long, proteolytically resistant gluten peptide known as the 33-mer, which has been associated with an adverse immune response in celiac disease. The digestion efficacy of AMYNOPEP on the 33-mer was first assessed in vitro , demonstrating end-to-end degradation of the gluten immunogenic peptide into single amino acids and dipeptides. These in vitro results were then validated in a crossover study of 14 healthy volunteers who received stable isotope-labelled 33-mer with and without AMYNOPEP. The study clearly showed that AMYNOPEP enhanced 33-mer digestion kinetics within minutes, significantly increasing levels of stable isotope-labelled amino acids detected in blood. Strikingly, AMYNOPEP improved 33-mer digestion even under “stress-test” conditions that included competing food substrates such as hydrolyzed whey protein and wheat gluten, revealing up to 3 times higher maximum concentrations of labelled amino acids in blood with AMYNOPEP compared to control. “The positive results of this proof-of-principle study pave the way for a new therapeutic enzyme paradigm leveraging specific exopeptidase combinations that support, enhance, or even replace the activity of critical endogenous enzymes lining the small intestine,” said Dr. Sulay Mourabit, CSO of AMYRA and co-lead author on the study. In the human gastrointestinal tract, most exopeptidases are found at the intestinal brush border membrane, which is sensitive to inflammatory damage. These exopeptidases are essential for completing protein digestion by cleaving peptides from end-to-end, generating absorbable amino acids. He added: “As single agents, exopeptidases are inefficient as they have limited substrate range, and we see this with DPP-IV supplements currently on the market. AMYRA specializes in developing unique combinations of exopeptidases with complementary and enhanced activity, designed to thoroughly break down proteolytically resistant food peptides. Ultimately, complex digestive diseases such as celiac may require a combination of treatment approaches. Given the critical role of the exopeptidase machinery in the human GI tract, and the vulnerability of the intestinal brush border membrane to chronic inflammatory damage, we’re excited to see the role that AMYNOPEP will play in digestive disease therapeutics.” “This is an encouraging and far-reaching proof-of-principle study demonstrating the validity and therapeutic relevance of our approach,” said Dr. Werner Tschollar, CEO and founder of AMYRA and senior author of the study. “As a next step, AMYRA is planning further clinical studies to investigate AMYNOPEP’s enzyme efficacy, immune response suppression, and symptom relief in patients with celiac disease. We strongly believe that supplementing the body with specific exopeptidases will prove to be a valuable adjunct therapy to the gluten-free diet, which alone represents a suboptimal solution.” About AMYRA Biotech AG AMYRA Biotech AG is a privately held biotech company developing novel therapeutic solutions for patients suffering from dietary peptide-driven disorders including celiac disease, gluten sensitivity, and other gastrointestinal disorders. The Company’s proprietary enzyme combinations have the unique capability of rapidly and systematically digesting proteolytically resistant gluten peptides from one end to the other, generating harmless and absorbable degradation products in the small intestine.  AMYRA is based in Basel, Switzerland. For further information, please visit www.amyra.com. About AMYNOPEP Several digestive enzyme supplements on the market and therapeutics under development seek to help the body break down hard-to-digest gluten peptides, which are known to trigger adverse reactions in individuals with gluten-related health disorders. The vast majority of these are endopeptidases that target gluten digestion in the stomach and generate smaller protein fragments (peptides) that may retain the ability to trigger an inflammatory response. In contrast, AMYNOPEP is a novel therapeutic enzyme principle based on specific combinations of exopeptidases that thoroughly degrade gluten peptides from end-to-end in the small intestine, generating individual, easily absorbable, and harmless amino acids and dipeptides that are incapable of triggering an immune response. AMYRA’s lead exopeptidase combination, AMYNOPEP, is capable of digesting proline-rich, hard-to-digest peptides found in foods such as gluten, which is notoriously linked to gastrointestinal distress. SOURCE: AMYRA Biotech

PITTSBURGH, May 23, 2024 /PRNewswire/ -- "We thought there could be a better way to keep track of when a baby bottle was filled or how long it has been at room temperature," said one of two inventors, from Salt Lake City, Utah, "so we invented the IMPROVED BABY BOTTLE. Our design would be a valuable accessory for busy parents, and it could provide added health benefits for babies." The patent-pending invention provides an improved design for a baby bottle. In doing so, it offers a reminder of how long baby formula or milk has been at room temperature. As a result, it prevents the baby from drinking milk that may be spoiled or close to spoiled. It also helps prevent excess air intake that can lead to painful gas and colic symptoms. The invention features a user-friendly design that is easy to use so it is ideal for parents with babies. Additionally, a prototype model is available upon request. The original design was submitted to the Salt Lake City sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 22-SGJ-245, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at . SOURCE InventHelp

New Study Offering Free Plagiocephaly Treatment (an alternative to helmet therapy) in San Diego, California! SAN DIEGO, March 27, 2024 /PRNewswire/ -- The Osteopathic Center for Children & Osteopathy's Promise to Children is now looking for infants 4 months old and younger diagnosed with plagiocephaly (flat head syndrome), which affects 47% of infants in the US. If left untreated, this can cause vision problems, muscular tightness, dental issues, & developmental delays. Qualified infants who enroll in this study will receive gentle, hands-on treatment known as Osteopathic Manipulative Treatment (OMT), which has been proven to address the underlying cause of plagiocephaly, reducing its impact on the child's development more than current treatments, such as helmet therapy. Continue Reading If you think that your child has plagiocephaly/flat head syndrome, reach out to see how you can participate in the study. You may qualify for free Osteopathic Manipulative Treatment (OMT) and up to $550 in compensation! "We use OMT to evaluate & treat the whole body, not just one area of concern. Parents who have brought their children for OMT have seen incredible results. Often when treating them for plagiocephaly, we also see improvement in other conditions such as feeding problems, colic, poor sleep, spitting up, and torticollis (tight neck muscles)," says Dr. Kimberly Wolf, DO, FAAP, FACOP, FAAPO who is one of the leaders in the field of pediatric osteopathic medicine. Parents or referring doctors can visit for more information. About Plagiocephaly Plagiocephaly, known as flat head syndrome, is a condition where an infant's head becomes flattened on one side. Torticollis is characterized by tight neck muscles, restricting an infant's ability to turn their head. Plagiocephaly & torticollis diagnoses have risen nearly 600% since the launch of the Back to Sleep Campaign to reduce Sudden Infant Death Syndrome (SIDS)/Sudden Unexpected Infant Death (SUID) in 1992. It is estimated that ~47% of 3-month-olds may have plagiocephaly. Currently, plagiocephaly management may involve repositioning or wearing a corrective helmet for several months, which mainly addresses the cosmetic aspect of plagiocephaly. About OMT Both published & anecdotal evidence support the success of OMT. A 2023 study in the Journal of Osteopathic Medicine shows that following OMT treatments, there was a statistically significant decrease in the measure of skull asymmetry & head flattening. Additionally, the mom of a patient treated by Dr. Wolf shared, "My child had plagiocephaly as an infant. We were able to bypass having to use a helmet by taking him for OMT treatments & an amazing D.O. OMT is a WONDERFUL thing." The Benefits of OMT: - Administered by a physician. - Non-invasive and gentle. - Evaluates and treats the whole body, not just the head. About the OPT-IN Study The OPT-IN research study provides an alternative to helmet therapy. It hopes to show significant improvements in children receiving OMT compared to repositioning (at-home exercises) in children diagnosed with plagiocephaly. How to Enroll in the Study Healthcare providers in San Diego, CA, who have patients with plagiocephaly should refer families to OPT-IN for screening. Parents who are concerned about the shape of their child's head or whose child has plagiocephaly should contact OPT-IN for more information & to see if they qualify for the study. Children receive treatment in the study free of charge, and families will be compensated up to $550 for their participation. About Us: The Osteopathic Center for Children (OCC) aims to enhance children's well-being through holistic, patient-centered care and to promote osteopathic principles in pediatric medicine. Our mission includes research, education, & supporting physicians in providing osteopathic care to children & families. Social media: Facebook: LinkedIn Media Contact: Kimberly Wolf, DO Osteopathic Center for Children Osteopathy's Promise to Children Phone: 619-693-6303 Email: [email protected] SOURCE Osteopathy’s Promise to Children